ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL
August 09, 2016 01:09 ET
|
Ablynx
ACR20, ACR50 and ACR70 scores of up to 79%, 59% and 43% respectively at week 24
Strong impact on disease activity with up to 49% of patients in clinical remission at week 24
Excellent...
BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX
August 04, 2016 01:11 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Aug. 4, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX ANNOUNCES WARRANT EXERCISE
July 20, 2016 01:08 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, July 20, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA
July 07, 2016 01:08 ET
|
Ablynx
ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24% respectively at week 12
Very encouraging efficacy data compared to tocilizumab with up to 41% of patients in clinical remission at week...
CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX
June 16, 2016 12:12 ET
|
Ablynx
GHENT, Belgium, June 16, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] issued a correction regarding a transparency notification received on 13 June 2016, pursuant to the...
VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX
June 16, 2016 01:08 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, June 16, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
June 14, 2016 01:12 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, June 14, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2...
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
June 10, 2016 12:07 ET
|
Ablynx
REGULATED INFORMATION
Ghent/Zwijnaarde, Belgium, June 10, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, as a result of the closing of its private...
ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016
June 03, 2016 01:06 ET
|
Ablynx
GHENT, Belgium, June 3, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its CEO, Dr Edwin Moses, will present a company update at the Annual Jefferies...
ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
May 26, 2016 01:24 ET
|
Ablynx
GHENT, Belgium, May 26, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that a post-hoc analysis of the worldwide Phase II TITAN study of its wholly-owned...